Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A9 | P48067 | 13/20 | 0.51 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.47 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | ATR | Q13535 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2470148 | 0.89 | SLC6A9 (0.46) | SLC6A9MCHR1P2RX7LMNAATR | |
| SCHEMBL2467928 | 0.86 | SLC6A9 (0.51) | SLC6A9P2RX7LMNAATR | |
| SCHEMBL2470323 | 0.86 | SLC6A9 (0.45) | SLC6A9MCHR1 | |
| SCHEMBL2496825 | 0.84 | SLC6A9 (0.43) | SLC6A9MCHR1P2RX7LMNA | |
| SCHEMBL13175412 | 0.83 | SLC6A9 (0.46) | SLC6A9P2RX7 | |
| SCHEMBL2491201 | 0.82 | MCHR1 (0.49) | SLC6A9MCHR1LMNA | |
| SCHEMBL13594085 | 0.82 | P2RX7 (0.42) | SLC6A9P2RX7LMNAATR | |
| SCHEMBL2473533 | 0.82 | P2RX7 (0.42) | SLC6A9P2RX7LMNAATR | |
| SCHEMBL2469913 | 0.81 | P2RX7 (0.45) | P2RX7LMNAATR | |
| SCHEMBL2468582 | 0.81 | HDAC3 (0.51) | SLC6A9MCHR1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2371366-A1 | Heterocyclo inhibitors of potassium channel function | Bristol-Myers Squibb Company (US) | 2011-10-05 | — | — | EP | disclosed |
| US-20090312307-A1 | HETEROCYCLO INHIBITORS OF POTASSIUM CHANNEL FUNCTION | BRISTOL-MYERS SQUIBB COMPANY | 2009-12-17 | — | — | US | disclosed |
| US-20090312307-A1 | HETEROCYCLO INHIBITORS OF POTASSIUM CHANNEL FUNCTION | BRISTOL-MYERS SQUIBB COMPANY | 2009-12-17 | — | — | US | disclosed |
| US-7582654-B2 | Heterocyclo inhibitors of potassium channel function | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-09-01 | — | — | US | disclosed |
| US-7582654-B2 | Heterocyclo inhibitors of potassium channel function | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-09-01 | — | — | US | disclosed |
| US-7005436-B2 | Heterocyclo inhibitors of potassium channel function | BRISTOL MYERS SQUIBB COMPANY (US) | 2006-02-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090312307-A1 | HETEROCYCLO INHIBITORS OF POTASSIUM CHANNEL FUNCTION | KCNJ2, KCNH2, KCNQ5 | SLC6A9 2351/4885MCHR1 3383/4885P2RX7 518/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.